Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals announced that it has initiated its Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090 in patients undergoing cataract surgery.

A molecular receptor pivotal to the action of male hormones such as testosterone also plays a crucial role in the body’s ability to heal, report scientists in the December issue of the Journal of Clinical Investigation.

InSite Vision Incorporated (OTCBB: INSV), a company developing ophthalmic products for unmet eye care needs, announced plans to advance new development candidate ISV-303, a topical anti-inflammatory product intended to reduce the pain and swelling associated with ocular surgery. InSite Vision formulated a lower concentration of bromfenac with its proprietary DuraSite® technology to create a proprietary [...]

Chemists and biologists from the University of Bath have developed a new technique that could be used to diagnose and develop treatments for age-related conditions like Alzheimer’s disease, diabetes and cancer.

New research published in Cell proposes that delaying ageing in mice models could protect them from symptoms linked to Alzheimer’s disease.
The scientists who undertook the study in the US suggest this could lead to development of new drug treatments in Alzheimer’s disease.